Asia Spotlight: China’s First TCM Law Excites Industry Looking For Cheer
A long-awaited new law that could greatly enlarge the market for traditional Chinese medicines has prompted domestic drug makers in China to race to develop new products, but could it also hurt multinational drug companies in the country?
You may also be interested in...
Sweeping regulatory reforms put China in catch-up mode for the approval of oncology drugs, some of which have been cleared for marketing only in the country. But how does the deluge of new products measure up in terms of actual overall survival benefits? A new study by Peking University scholars and specialists unveils some surprising results.
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.